 NEW YORK, Dec. 11, 2020 GLOBE NEWSWIRE -- Delcath Systems, Inc. Nasdaq: DCTH, an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced the completion of an underwritten public offering of 1,679,031 shares of its common stock, including 219,004 shares sold pursuant to the full exercise of an option previously granted to the underwriters to purchase additional shares of common stock. All of the shares were offered by Delcath at a price to the public of 13.25 per share. The Company now estimates that the gross proceeds of the offering to the Company are expected to be approximately 22.2 million, before deducting the underwriting discounts and commissions and other estimated offering expenses. 